89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression

• Published in: The Journal of nuclear medicine (1978) Vol. 62; no. 5; pp. 656 - 664
• Main Authors: Jung, Kyung-Ho, Park, Jin Won, Lee, Jin Hee, Moon, Seung Hwan, Cho, Young Seok, Lee, Kyung-Han
• Format: Journal Article
• Language: English
• Published: New York Society of Nuclear Medicine 10.05.2021
• Subjects: AKT protein; Antibodies; Apoptosis; Basic Science Investigation; Binding; Blood; Chemotherapy; Cold treatment; Colon; Colon cancer; Colorectal cancer; Computed tomography; Conjugation; Deferoxamine; Disulfide bonds; Dosage; Electrophoresis; Flow cytometry; Gel electrophoresis; Gemcitabine; Homology; Image analysis; Image processing; Immune clearance; Intravenous administration; Ionization; Kinases; L1 protein; Medical imaging; Modulation; PD-L1 protein; Pharmacokinetics; Polyacrylamide; Positron emission; Proteins; PTEN protein; Radiolabelling; Reduction; Sodium dodecyl sulfate; Sodium lauryl sulfate; Tensin; Tomography; Tumors; Western blotting; Zirconium isotopes

We developed an 89Zr-labeled anti–programmed death ligand 1 (anti-PD-L1) immune PET that can monitor chemotherapy-mediated modulation of tumor PD-L1 expression in living subjects. Methods: Anti-PD-L1 underwent sulfohydryl moiety–specific conjugation with maleimide-deferoxamine followed by 89Zr radio...